Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology-

References

• Barnas C, Tauscher J, Küfferle B, Krenn P, Asenbaum S, Brücke T, Kasper S. 123I‐IBZM SPECT imaging of dopamine‐2 receptors in psychotic patients treated with zotepine. Eur Neuro‐psychopharmacol 1997; 7(2)S215
   Google Scholar
• Barnas C, Quiner S, Tauscher J, Willeit M, Küfferle B, Asenbaum S, Brücke T, Rao M L., Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine‐2 receptor occupancy in schizophrenic patients. Psychopharmacology 2001; 157: 236–242
   PubMed Web of Science ®Google Scholar
• Bremner J D., Bronen R A., De Erasquin C, Vermetten E, Staib L H., Ng C K. Development and reliability of a method for using magnetic resonance imaging for the definition of regions of interest for positron emission tomography. Clin Pos Imag 1998; 1: 145–159
   PubMedGoogle Scholar
• Broich K, Alavi A, O'Brien C P., Galloway S, Mozley D. Imaging of dopamine D2 receptors with [123I] IBZM in normal controls with escalating doses of haloperidol. J Nucl Med 1992; 33: 898
   Google Scholar
• Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991a; 11: 220–228
   PubMed Web of Science ®Google Scholar
• Brücke T, Podreka I, Wenger S, Angelberger P, Müller C, Walter H. Dopamine receptor imaging with SPECT: A tool in extrapyramidal disorders and in vivo assay for the measurement of receptor blockade by neuroleptic treatment. J Cereb Blood Flow Metab 1991b; 11(Suppl 2)877
   Google Scholar
• Brücke T, Roth J, Podreka L, Strobl R, Wenger S, Asenbaum S. Striatal dopamine D2 receptor blockade by typical and atypical antipsychotics (letter). Lancet 1992; 339: 497
   PubMed Web of Science ®Google Scholar
• Brücke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]‐b‐CIT. Binding kinetics in the human brain. J Neural Transm 1993; 94: 137–146
   Web of Science ®Google Scholar
• Cambon H, Baron J C., Boulenger J P., Loch C, Zarifian E, Maziere B. In vivo assay for neuroleptic receptor binding in the striatum: positron tomography in humans. Br J Psychiatry 1987; 151: 824–830
   PubMed Web of Science ®Google Scholar
• Cordes M, Henkes H, Laudahn D, Brau H, Kramp W, Girke W, Hierholzer J, Eichstadt H, Felix R. Initial experience with SPECT examinations using [123I]IBZM as a D2‐dopamine receptor antagonist in Parkinson's disease. Eur J Radiol 1991; 12: 182–186
   PubMed Web of Science ®Google Scholar
• Dresel S, Mager T, Rossmuller B, Meisenzahl E, Hahn K, Moller H J., Tatsch K. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine‐123 iodobenzamide single‐photon emission tomography study. Eur J Nucl Med 1999; 26: 862–868
   PubMedGoogle Scholar
• Farde I, Nyberg S. Dosing determination for novel antipsychotics—a PET‐bases approach. Int J Psychiatry Clin Prac 1998; 2(Suppl 1)S39–S42
   Google Scholar
• Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258–261
   PubMed Web of Science ®Google Scholar
• Farde L, Halldin C, Müller L, Subara T, Karlson P, Hall H. PET study of [11C]β‐CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994; 16: 93–103
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom A L., Wiesel F A. Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538–544
   PubMed Web of Science ®Google Scholar
• Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Eriksson B. Positron emission tomography studies on D2 and 5HT2 receptor binding in risperidone treated patients. J Clin Psychopharmacol 1995; 15(Suppl 1)19S–23S
   Web of Science ®Google Scholar
• Fletcher A, Cliffe I A., Dourish C T. Silent 5‐HTIA receptor antagonists: utility as research tools and therapeutic agents. Trens Pharmacol Sci 1993; 14: 41–48
   PubMed Web of Science ®Google Scholar
• Friston K J., Holmes A P., Worsley K J., Poline J P., Frith C D., Frackowiack R SJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping 1995; 2: 189–210
   Google Scholar
• Gallhofer B. Is cognition influenced by second generation antipsychotics?. Int J Psychiatry Clin Prac 1998; 2(Suppl 2)S15–S19
   Google Scholar
• Gefvert O, Lindstrom L H., Langstrom B, Bergstrom M, Lundberg T, Yates R A. Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg “Seroquel”. Eur Neuropsychopharmacol 1996; 6(Suppl 3)74
   Google Scholar
• Goff D C., Midha K K., Brotman A W., McCormick S, Waites M, Amico E T. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193–197
   PubMed Web of Science ®Google Scholar
• Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP‐Studie, R Grohmann, E Rüther, L G. Schmidt. Springer, Berlin 1994
   Google Scholar
• Gunn R N., Lammertsma A A., Hume S P., Cunningham V J. Parametric imaging of ligand‐receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279–287
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5‐HTIA receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991; 48: 355–363
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C. Differential changes in serotonin 5‐HTIA and 5‐HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 1993; 112: S35–S39
   Web of Science ®Google Scholar
• Houle S, DaSilva J N., Wilson A A. Imaging the 5‐HT(1A) receptors with PET: WAY‐100635 and analogues. Nucl Med Biol 2000; 27: 463–466
   PubMed Web of Science ®Google Scholar
• Jones D W., Gorey G J., Zajicek K, Das B, Urbina R A., Lee K S. Depletion‐restoration studies reveal the impact of endogeneous dopamine and serotonin on [123I]‐β‐CIT SPECT imaging in primate brain (abstract). J Nucl Med 1998; 39: 42
   PubMed Web of Science ®Google Scholar
• Kane J M. Schizophrenia. N Engl J Med 1996; 334: 34–41
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Serotonin‐dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153: 466–476
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158: 360–369
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R. High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: A PET study. Am J Psychiatry 1996; 153: 948–950
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R B., Remington G, Jones C, DaSilva J, Wilson A A., Houle S. 5‐HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921–928
   PubMed Web of Science ®Google Scholar
• Karbe H, Wienhard K, Hamacher K, Huber M, Herholz K, Coenen H H. Positron emission tomography with (18F) methyl‐spiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm Gen Sect 1991; 86(3)163–173
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Küfferle B, Asenbaum S, Barnas C, Heßelmann B, Podreka I, Brücke T. Sertindole and dopamine D2 receptor occupancy. Biol Psychiatry 1997; 42(Suppl 1)161
   Google Scholar
• Kasper S, Tauscher J, Küfferle B, Barnas C, Heßelmann B, Asenbaum S, Podreka I, Brücke T. Sertindole and dopamine D., receptor occupancy in comparison to risperidone, clozapine and haloperidol—a 123I‐IBZM SPECT study. Psychopharmacology 1998a; 136: 367–373
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Küfferle B, Heßelmann B, Barnas C, Brücke T. IBZM‐SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. Eur Psychiatry 1998b; 13(Suppl 1)9s–14s
   PubMed Web of Science ®Google Scholar
• Kasper S, Küfferle B, Tauscher J, Barnas C, Brücke T. Receptor imaging studies in schizophrenia and their clinical relevance. Psychiatry Research—Neuroimaging 1998c; 83: 37–55
   Google Scholar
• Kasper S, Tauscher J, Küfferle B, Barnas C, Pezawas L, Quiner S. Dopamine‐and serotonin‐receptors in schizophrenia: Results of imaging‐studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 4)83–89
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Heiden A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001; 11(Suppl 4)S405–S413
   Google Scholar
• Handbook of depression and anxiety, S Kasper, I MA Sitsen, J den Boer. Marcel Dekker Inc, New York, In Press
   Google Scholar
• Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze A L., Möller H J., Biersack H J. (123I) IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996; 153: 183–190
   PubMed Web of Science ®Google Scholar
• Küfferle B, Brücke T, Tauscher J, Schratzberger‐Topitz A, Asenbaum S, Podreka I, Kasper S. IBZM‐SPECT and D2‐dopamine receptor occupancy: different profiles with atypical neuroleptics. Eur Neuropsychopharmacol 1995; 5: 337
   Google Scholar
• Küfferle B, Brücke T, Topitz‐Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S. Striatal dopamine‐2 receptor occupancy in psychotic patients treated with risperidone. Psychiatr Res—Neuroimaging 1996; 68: 23–30
   PubMed Web of Science ®Google Scholar
• Küfferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brücke T, Kasper S. IBZM SPECT imaging of striatal dopamine‐2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and halopendol. Psychopharmacology 1997; 133: 323–328
   PubMed Web of Science ®Google Scholar
• Lammertsma A A., Hume S P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153–158
   PubMed Web of Science ®Google Scholar
• Laruelle M, Baldwin R M., Malison R T., Zea‐Ponce V, Zoghbi S S., Al‐Tikriti M S., Sybirska E H., Zimmermann R C., Wisniewski C, Neumeyer J L. SPECT imaging of dopamine and serotonin transporter with [123I]β‐CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295–309
   PubMed Web of Science ®Google Scholar
• Laruelle M, Wallace E, Seibyl J P., Zea‐Ponce Y, Zoghbi S S., Neumeyer J L. Graphical, kinetic, and equilibrium analyses of in vivo [123I]‐β‐CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982–994
   PubMed Web of Science ®Google Scholar
• Lennkh C, de Zwaan M, Kasper S. New aspects of diagnosis and pharmacotherapy of eating disorders. Int J Psychiatry Clin Prac 1997; 1: 21–35
   PubMedGoogle Scholar
• Malison R T., Price L H., Berman R, van Dyck C H., Pelton G H., Carpenter L. Reduced brain serotonin transporter availability in major depression as measured by [123I]‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998; 44: 1090–1098
   PubMed Web of Science ®Google Scholar
• McCarron J A., Turton D R., Pike W V., Poole K G. Remotely controlled production of the 5‐HT14 receptor radioligand, [carbonyl‐11C]WAY‐100635, via 11C‐carboxylation of an immobilized Gringard reagent. J Label Compounds Radiopharm 1996; 38: 941–953
   Web of Science ®Google Scholar
• Melzer H Y. Clinical studies on the mechanism of action of clozapine: The dopamine: serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18–S27
   Web of Science ®Google Scholar
• Meyer J H., Gunn R N., Myers R, Grasby P M. Assessment of spatial normalization of PET ligand images using ligand‐specific templates. Neuroimage 1999; 9: 545–553
   PubMed Web of Science ®Google Scholar
• Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 1998; 23: 207–214
   PubMed Web of Science ®Google Scholar
• Mintun M A., Raichle M E., Kilbourn M R., Wooten G F., Welch M J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217–227
   PubMed Web of Science ®Google Scholar
• Möller H J. The state of evaluation and clinical benefits of atypical neuroleptics. The treatment of schizophrenia—Status and emerging trends, H D. Brenner, W Böker, R Genner. Hogrefe & Huber Publishers, Seattle, Toronto, Göttingen 2001; 29–44
   Google Scholar
• Montgomery S A., Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram—a meta‐analysis of nine placebo‐controlled studies. International Clinical Psychopharmacology 1994; 9(Suppl 1)35–40
   PubMed Web of Science ®Google Scholar
• Neumeister A, Pirker W, Willeit M, Praschak‐Rieder N, Asenbaum S, Brücke T, Kasper S. Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 2000; 47: 158–160
   PubMed Web of Science ®Google Scholar
• Neumeister A, Willeit M, Praschak‐Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychological Medicine 2001; 31: 1467–1473
   PubMed Web of Science ®Google Scholar
• Neumeyer J L., Wang S, Milius R A., Baldwin R M., Zea‐Ponce Y, Hoffer P B. [123I]‐2‐β‐carbomethoxy‐3‐β‐(4′‐iodophenyl)‐tropane ([123I]‐β‐CIT): High affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991; 34: 3144–3146
   PubMed Web of Science ®Google Scholar
• Neumeyer J L., Tamagnan G, Wang S, Gao Y, Milius R A., Kula N S., Baldessarini R J. N‐substituted analogs of 2 beta‐carbomethoxy‐3 beta‐(4′‐iodophenyl)tropane (beta‐CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996; 39: 543–548
   PubMed Web of Science ®Google Scholar
• Newman‐Tancredi A, Chaput C, Verriele L, Millan M J. Clozapine is a partial agonist at cloned, human serotonin 5‐HTIA receptors. Neuropharmacology 1996; 35: 119–121
   PubMed Web of Science ®Google Scholar
• Nordström A L., Farde L, Halldin C. High 5‐HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993; 110: 365–367
   PubMed Web of Science ®Google Scholar
• Nordström A L., Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2 and 5‐HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152: 1444–1449
   PubMed Web of Science ®Google Scholar
• Nordström A L., Nyberg S, Olsson H, Farde L. PET finding of a high striatal D2 receptor occupancy in olanzapine treated patients. Arch Gen Psychiatry 1998; 55: 238–248
   Web of Science ®Google Scholar
• Nyberg S. Relationships among extrapyramidal symptoms, antipsychotic drug doses and neuroreceptor occupancy. Int J Psychiatry Clin Prac 1998; 2(Suppl 2)S33–S39
   Google Scholar
• Nyberg S, Nakashima Y, Nordström A L., Halldin C, Farde L. Positron emission tomography of in vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5HT2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168(Suppl 29)40–44
   Google Scholar
• Nyberg S, Farde L, Halldin C. A PET study of 5HL2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16: 1–7
   PubMed Web of Science ®Google Scholar
• Pilowsky L S., Costa D C., Ell P J., Murray R M., Verhoeff N PLG, Kerwin R W. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199–202
   PubMed Web of Science ®Google Scholar
• Pilowsky L S., Busatto G F., Taylor M, Costa D C., Sharma T, Sigmundsson T. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine—a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124: 148–153
   PubMed Web of Science ®Google Scholar
• Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, Neumeister A, Praschak‐Rieder N, Angelberger P, Brücke T. Imaging serotonin and dopamine transporter with iodine‐123‐CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med 2000; 41: 36–44
   PubMed Web of Science ®Google Scholar
• Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brücke T. β‐CIT SPECT demonstrates blockade of 5HT‐uptake sites by citalopam in the human brain in vivo. Journal of Neural Transmission (Gen) 1995; 100: 247–256
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman A. Serotonergic agents in the treatment of acute neuroleptic‐induced akathisia: open‐label study of buspirone and mianserin. Int Clin Psychopharmacol 1997; 12: 263–268
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876–884
   PubMed Web of Science ®Google Scholar
• Stamenkovic M, Schindler S D., Asenbaum S, Neumeister A, Aschauer H N., Willeit M, Willinger U, de Zwaan M, Kasper S. No change in striatal dopamine reuptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: A (123I)‐β‐CIT SPECT‐study. Eur Neuro‐psychopharmacol 2001; 11: 69–74
   PubMed Web of Science ®Google Scholar
• Studholme C, Hill D L., Hawkes D J. Automated three‐dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25–35
   PubMed Web of Science ®Google Scholar
• Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. Thieme, New York 1988
   Google Scholar
• Tarazi F I., Zhang K, Baldessarini R J. Long‐term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. The Journal of Pharmacology and Experimental Therapeutics 2001; 297: 711–717
   PubMed Web of Science ®Google Scholar
• Tauscher J, Küfferle B, Asenbaum S, Brücke T, Kasper S. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine‐2 receptor occupancy with quetiapine. Psychopharmacology 1997; 133: 102–105
   PubMed Web of Science ®Google Scholar
• Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher‐Wisniewski S, Brücke T, Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine‐2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999a; 141: 175–181
   PubMed Web of Science ®Google Scholar
• Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brücke T, Kasper S. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuro‐psychopharmacol 1999b; 9: 177–179
   PubMed Web of Science ®Google Scholar
• Tauscher J, Pirker W, Willeit M, De Zwaan M, Bailer U, Neumeister A, Asenbaum S, Lennkh C, Praschak‐Rieder N, Brücke T, Kasper S. [123I] β‐CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biological Psychiatry 2001a; 49: 326–332
   PubMed Web of Science ®Google Scholar
• Tauscher J, Verhoeff N P., Christensen B, Hussey D, Meyer J, Kecojevic A, Javanmard M, Kasper S, Kapur S. Serotonin 5HT‐1A receptor binding potential declines with age as measured by (11C)way‐100635 and PET. Neuropsychopharmacology 2001b; 24: 522–530
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kapur S, Verhoeff P LC, Hussey D F., Daskalakis Z J., Tauscher‐Wisniewski S, Kasper S, Zipursky R B. Brain serotonin 5‐HTIA receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY‐100635. Archives of General Psychiatry 2002a; 59: 514–520
   PubMed Web of Science ®Google Scholar
• Tauscher J, Küfferle B, Asenbaum S, Tauscher‐Wisniewski S, Kasper S. Striatal dopamine‐2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002b; 162: 42–49
   PubMed Web of Science ®Google Scholar
• Tejani‐Butt S M. [3H]‐Nisoxetine: A radioligand for quantification of norepinephrine uptake sites by autoradiography or homogenate binding. J Pharmacol Exp Ther 1992; 260: 427–436
   PubMed Web of Science ®Google Scholar
• Willeit M, Praschak‐Rieder N, Neumeister A, Pirker W, Vitouch O, Asenbaum S, Brücke T, Tauscher J, Kasper S. (123JI)‐β‐CIT SPECT imaging shows reduced brain serotonin transporter availability in drug free depressed patients with seasonal affective disorder. Biol Psychiatry 2000; 47: 482–489
   PubMed Web of Science ®Google Scholar
• Willeit M, Stastny J, Pirker W, Praschak‐Rieder N, Neumeister A, Asenbaum S, Tauscher J, Fuchs K, Sieghart W, Hornik K, Aschauer H N., Brücke T, Kasper S. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 2001; 50: 8–12
   PubMed Web of Science ®Google Scholar